ClinicalTrials.gg
CompletedNCT02289430NVP-1205Updated Mar 25, 2016

to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers

A Phase 1 interventional study of Crestor+Ezetrol and Ezetrol in Healthy, sponsored by NVP Healthcare. Completed. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-25.

Sponsored by NVP Healthcare · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the drug interaction of pharmacokinetics of rosuvastatin and ezetimibe.

Read the detailed description

drug interaction : rosuvastatin, ezetimibe

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

NVP Healthcare is the lead sponsor of 22 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects age between 19 and 45 singed

Exclusion criteria

Exclusion Criteria:

  • Hypotension or hypertension has a history of allergy reaction of this drug or other drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Crestor+Ezetrol

    rosuvastatin+ezetimibe

    Drug: Crestor+Ezetrol

  • Active comparator
    Ezetrol

    ezetimibe

    Drug: Ezetrol

  • Active comparator
    Crestor

    rosuvastatin

    Drug: Crestor

Interventions

  • DrugCrestor+Ezetrol

    Drug pages: Rosuvastatin · Ezetimibe

    rosuvastatin+ezetimibe

    Also known as: rosuvatatin+ezetimibe

  • ezetimibe

    Also known as: ezetimibe

  • rosuvastatin

    Also known as: rosuvastatin

06

What researchers measure

Primary outcomes

  1. Area Under Curve

    Time frame: 0-24h

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2014
First posted
Nov 13, 2014
Start
Dec 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Mar 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02289430
Lead sponsor
NVP Healthcare
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Dec 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Mar 25, 2016

Study contacts

Shin D Seong, M.D.
principal investigator · Gachon University Gil Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion